The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Leslie A. Fecher; Shrinivas Bishu; Robert J. Fontana; Salim S. Hayek; Bryan J. Schneider

doi:10.6004/jnccn.2022.7011

The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, Bryan J. Schneider

Research output: Contribution to journal › Review article › peer-review

Abstract

Immune checkpoint inhibitors have revolutionized the treatment of cancer and are now omnipresent. However, immune-related adverse events can present with varying phenotypes and timing, which can pose diagnostic and therapeutic challenges for the treating oncologist as well as subspecialty consultants. Biopsies of affected organs may provide insight into biologic mechanisms as well as potentially guide management in certain circumstances.

Original language	English (US)
Pages (from-to)	417-425
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2022.7011
State	Published - Apr 2022
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.7011

Cite this

@article{2ea05f281ece4721b2cdafead11114a4,

title = "The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity",

abstract = "Immune checkpoint inhibitors have revolutionized the treatment of cancer and are now omnipresent. However, immune-related adverse events can present with varying phenotypes and timing, which can pose diagnostic and therapeutic challenges for the treating oncologist as well as subspecialty consultants. Biopsies of affected organs may provide insight into biologic mechanisms as well as potentially guide management in certain circumstances.",

author = "Fecher, {Leslie A.} and Shrinivas Bishu and Fontana, {Robert J.} and Hayek, {Salim S.} and Schneider, {Bryan J.}",

year = "2022",

month = apr,

doi = "10.6004/jnccn.2022.7011",

language = "English (US)",

volume = "20",

pages = "417--425",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "4",

}

TY - JOUR

T1 - The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

AU - Fecher, Leslie A.

AU - Bishu, Shrinivas

AU - Fontana, Robert J.

AU - Hayek, Salim S.

AU - Schneider, Bryan J.

PY - 2022/4

Y1 - 2022/4

N2 - Immune checkpoint inhibitors have revolutionized the treatment of cancer and are now omnipresent. However, immune-related adverse events can present with varying phenotypes and timing, which can pose diagnostic and therapeutic challenges for the treating oncologist as well as subspecialty consultants. Biopsies of affected organs may provide insight into biologic mechanisms as well as potentially guide management in certain circumstances.

AB - Immune checkpoint inhibitors have revolutionized the treatment of cancer and are now omnipresent. However, immune-related adverse events can present with varying phenotypes and timing, which can pose diagnostic and therapeutic challenges for the treating oncologist as well as subspecialty consultants. Biopsies of affected organs may provide insight into biologic mechanisms as well as potentially guide management in certain circumstances.

UR - http://www.scopus.com/inward/record.url?scp=85129007933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129007933&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.7011

DO - 10.6004/jnccn.2022.7011

M3 - Review article

C2 - 35390763

AN - SCOPUS:85129007933

SN - 1540-1405

VL - 20

SP - 417

EP - 425

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this